Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.43 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL664788 | 0.92 | CACNA2D1 (0.57) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL665175 | 0.92 | CACNA2D1 (0.57) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL4194017 | 0.92 | CACNA2D1 (0.57) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL1419512 | 0.90 | CACNA2D1 (0.41) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL5003775 | 0.90 | CACNA2D1 (0.41) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL1419510 | 0.90 | CACNA2D1 (0.41) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL8141648 | 0.87 | CACNA2D1 (0.62) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL4336387 | 0.87 | CACNA2D1 (0.62) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL4336389 | 0.87 | CACNA2D1 (0.62) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Hydrochloric Acid SCHEMBL14108565 | 0.86 | CACNA2D1 (0.60) | CACNA2D1CACNB3CACNA1CPGRADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110483317-B | Preparation method and application of 3-isobutyl dimethyl glutarate | 黄冈鲁班药业股份有限公司 | 2022-08-30 | — | — | CN | claimed |
| CN-110483317-A | The preparation method and application of high-purity 3- isobutylglutaric acid dimethyl ester | HUANGGANG LUBAN PHARMACEUTICAL CO LTD | 2019-11-22 | — | — | CN | claimed |
| WO-2019193607-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF PREGABALIN | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2019-10-10 | — | — | WO | claimed |
| CN-113564144-B | Lipase mutant and application thereof | 上海奥博生物医药股份有限公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-118956817-A | Lipase mutant and application thereof | 上海奥博生物医药股份有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-112048492-B | Ester hydrolase mutant | 尚科生物医药（上海）有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-116694694-A | Enzyme catalysis process for preparing pregabalin chiral intermediate | 尚科生物医药（上海）有限公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-110483317-B | Preparation method and application of 3-isobutyl dimethyl glutarate | 黄冈鲁班药业股份有限公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-110483317-B | Preparation method and application of 3-isobutyl dimethyl glutarate | 黄冈鲁班药业股份有限公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-110483317-B | Preparation method and application of 3-isobutyl dimethyl glutarate | 黄冈鲁班药业股份有限公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-113564144-A | Lipase mutant and application thereof | 上海奥博生物医药技术有限公司 | 2021-10-29 | — | — | CN | disclosed |
| CN-112048492-A | Ester hydrolase mutant | 尚科生物医药（上海）有限公司 | 2020-12-08 | — | — | CN | disclosed |
| CN-110483317-A | The preparation method and application of high-purity 3- isobutylglutaric acid dimethyl ester | HUANGGANG LUBAN PHARMACEUTICAL CO LTD | 2019-11-22 | — | — | CN | disclosed |
| CN-110483317-A | The preparation method and application of high-purity 3- isobutylglutaric acid dimethyl ester | HUANGGANG LUBAN PHARMACEUTICAL CO LTD | 2019-11-22 | — | — | CN | disclosed |
| CN-110483317-A | The preparation method and application of high-purity 3- isobutylglutaric acid dimethyl ester | HUANGGANG LUBAN PHARMACEUTICAL CO LTD | 2019-11-22 | — | — | CN | disclosed |
| WO-2019193607-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF PREGABALIN | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2019-10-10 | — | — | WO | disclosed |
| CN-108019740-A | A kind of biomass fuel boiler device and its method of work | 徐州工程学院 | 2018-05-11 | — | — | CN | disclosed |
| US-20080311635-A1 | PROCESS FOR THE PREPARATION OF (S)(+)-3-(AMINOMETHYL)-5-METHYLHEXANOIC ACID | DIPHARMA FRANCIS S.R.L. (IT) | 2008-12-18 | — | — | US | disclosed |
| EP-1992609-A1 | A process for the preparation of a (S)(+)-3-(aminomethyl)-5-methylhexanoic acid | Dipharma Francis S.r.l. (IT) | 2008-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311635-A1 | PROCESS FOR THE PREPARATION OF (S)(+)-3-(AMINOMETHYL)-5-METHYLHEXANOIC ACID | ADH5, ALDH7A1, ADH1C | CACNA2D1 360/4885CACNB3 575/4885CACNA1C 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.